Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 28, 2024	Dec. 31, 2023	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of stock options exercised	$ 1.7	$ 0.2
Weighted average grant date fair value of share-based awards granted	$ 97.61	$ 89.25
Weighted average grant date fair value of restricted stock units granted	$ 192.59
Total unrecognized compensation cost	$ 85.7
Unrecognized compensation cost, weighted average remaining requisite service period	2 years 11 months 15 days
Number of unvested options and restricted stock units	2,294,896
Common stock, shares issued	55,841,318			55,766,078
FlexBiosys
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued	2,770
Earnout consideration earned	20.00%
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance					2,778,000
Incentive options, vesting period	1,511,335
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period	5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of restricted stock units vested	$ 19.0	$ 24.3
Weighted average grant date fair value of restricted stock units granted	$ 192.59	$ 180.05
Restricted Stock Unit
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock			$ 183.92